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AbstrACt 
Introduction Cognitive behavioural therapies (CBTs) are 
one of the most effective treatments for major depression. 
However, ~50% of individuals do not adequately 
respond to intervention and of those who do remit from a 
depressive episode, over 50% will experience later relapse. 
Identification of patient-level factors which moderate 
treatment response may ultimately help to identify cognitive 
barriers that could be targeted to improve treatment 
efficacy. This individual patient data meta-analysis explores 
one such potential moderator—the ability to retrieve 
specific, detailed memories of the autobiographical past—
as cognitive-based therapeutic techniques draw heavily on 
the ability to use specific autobiographical information to 
challenge the dysfunctional beliefs which drive depression.
Methods and analysis We have formed a collaborative 
network which will contribute known datasets. This will 
be supplemented by datasets identified through literature 
searches in Medline, PsycInfo, Web of Science, the 
Cochrane Central Register of Controlled Trials and WHO trials 
database between December 2018 and February 2019. 
Inclusion criteria are delivery of a cognitive or cognitive 
behavioural therapy for major depression, and measurement 
of autobiographical memory retrieval at preintervention. 
Primary outcomes are depressive symptoms and clinician-
rated diagnostic status at postintervention, along with 
autobiographical memory specificity at postintervention. 
Secondary outcomes will consider each of these variables 
at follow-up. All analyses will be completed using random-
effects models employing restricted maximum likelihood 
estimation. Risk of bias in included studies will be measured 
using the Revised Cochrane Risk of Bias Tool.
Ethics and dissemination The findings will be published 
in a peer-reviewed journal. Study results will contribute 
to better understanding of the role of autobiographical 
memory in patient response to CBTs, and may help to 
inform personalised medicine approaches to treatment of 
depression.
PrOsPErO registration number CRD42018109673.
IntrOduCtIOn
Depression is the second leading cause of 
disability worldwide.1 The disorder costs the 
UK economy an estimated £7.5 billion per 
year, with this cost expected to increase.2 
Antidepressant medications (eg, selective 
serotonin reuptake inhibitors; tricyclic anti-
depressants) are effective in treating depres-
sion,3 4 but only so long as they are taken.5 6 
Despite efficacious psychological treatments 
such as interpersonal psychotherapy7 8 and 
cognitive behavioural therapies (CBTs),9 10 
only 40%–60% of National Health Service 
(NHS) patients experience recovery after 
receiving psychological intervention for 
depression.11 Of those who do respond, up 
to 50% will experience later relapse.12 Our 
gold-standard psychological interventions are 
therefore producing suboptimal outcomes 
for a significant number of individuals.
Improving treatment success rates is there-
fore a key priority for social, economic and 
health systems. Identification of patient-level 
factors which may interfere with the efficacy 
of psychological interventions and predis-
pose an individual towards poorer treatment 
response may help to explain differential 
response rates. If we consider CBTs, which 
are commonly administered in front-line 
strengths and limitations of this study
 ► This is the first individual patient data meta-analysis 
of the role of autobiographical memory in patient 
response to cognitive behavioural therapy (CBT) for 
major depression.
 ► This study may identify a patient-level moderator of 
response to CBTs.
 ► Results will advance understanding of whether CBTs 
improve this relapse risk factor.
 ► We anticipate that there may only be a small num-
ber of trials which have measured autobiographical 
memory, which may limit conclusions.
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NHS psychology services (eg, improving access to psycho-
logical therapies services),11 identification of cogni-
tive barriers which may impede the ability to complete 
cognitive therapy tasks may advance our understanding 
of exactly why some individuals respond poorly, or not 
at all. Similarly, cognitive predictors of depression which 
are not shifted by intervention may indicate relapse risk 
factors.13 Together, further understanding of patient-level 
factors that both impede treatment efficacy and/or are 
not shifted by treatment and go on to predict relapse may 
contribute to development of a personalised medicine 
approach14 for treatment of depression.
Autobiographical memory, our memory for personal 
life experiences, is one cognitive factor which plays an 
important role in the course of depression.15 In partic-
ular, the ability to retrieve specific, detailed memories of 
single incidents (eg, the occasion I met my partner) predicts 
future depressive symptoms over and above current 
symptom levels (for a meta-analysis, see Sumner et al).16 
The ability to retrieve specific autobiographical memo-
ries not only independently predicts prognosis (eg, by 
reducing the ability to solve problems or plan for the 
future17 18) but may also impede the ability to complete 
CBT for depression.
A core aim of both traditional and later wave CBTs is to 
change the way that an individual relates to dysfunctional 
thoughts about the self and world (originally outlined by 
Beck).19 Key therapeutic techniques encourage the indi-
vidual to identify links between thoughts and feelings, 
by recalling what they said to themselves, how that made 
them feel and how that led them to act in a recent situa-
tion (eg, going to a work function). For example, a core tech-
nique is to encourage the individual to not automatically 
accept thoughts as facts, but rather, to evaluate the accu-
racy of each thought (eg, no one wants to talk to me) using 
specific pieces of evidence recalled from the individual’s 
past (eg, last time I was at a work function I had a lovely conver-
sation with a colleague). The efficacy of such techniques is 
therefore likely to be influenced by an individual’s ability 
to recall detailed, specific information about their auto-
biographical past. Treatment manuals instruct cognitive 
therapists to enrich detail and encourage specificity in 
patient responses while they are completing such tasks; 
however, a moderating role of memory specificity in the 
efficacy of CBTs has yet to be explored.
Similarly, it is possible that this reduction in autobi-
ographical memory specificity may also be improved as 
a result of completing CBT. In continuously promoting 
a focus on specific information, and reducing the 
depressive tendency to overgeneralise information, CBT 
techniques may actively train an individual to be more 
specific. Indeed, increasing the specificity of thinking has 
been previously proposed as a key mechanism of effec-
tive CBT for depression.20 There is some prior literature 
which suggests that autobiographical memory specificity 
may improve following a course of cognitive-based inter-
vention, most notably CBT21 and mindfulness-based 
cognitive therapy.22 In contrast, evidence that reduced 
memory specificity persists between depressive episodes16 
may indicate that this relapse risk factor is not commonly 
shifted by treatment. Determining the impact of CBTs on 
autobiographical memory specificity, relative to natural 
recovery, antidepressant medication and other active 
psychological interventions, will advance our under-
standing of how treatment impacts this relapse risk factor, 
and offer important implications for the adjunctive use 
of autobiographical memory-based interventions (for 
review, see Barry et al23; Hitchcock et al)24 to enhance 
treatment outcomes.
The lack of prior investigation of the interaction 
between autobiographical memory specificity and CBTs 
has largely been due to a lack of statistical power to 
examine moderation effects in prior studies. Prior trials 
of CBTs which have included a measure of autobiograph-
ical memory have recruited small sample sizes (eg, n=21 
in the Mindfulness Based Cognitive Therapy (MBCT) 
group in Williams et al),22 and thus been underpowered 
to explore these effects. Completion of individual patient 
data meta-analysis (IPD-MA) can overcome this issue. The 
IPD-MA approach involves synthesis of patient-level data 
across multiple studies, thereby offering greater statistical 
potential to explore individual characteristics and how 
these interact with treatment effects, relative to aggregate 
meta-analysis which synthesises data at the study level.25 
We have therefore formed a collaborative network to 
allow us to complete an IPD-MA evaluating the nature of 
autobiographical memory specificity in patient response 
to cognitive behavioural treatment for depression.
Specifically, we will address the following questions:
1. First, does treatment for depression (a) induce a 
change in autobiographical memory specificity? and 
(b) induce a stronger change following CBTs relative 
to other interventions?
2. Second, does the specificity of autobiographical mem-
ory at baseline predict treatment response (a) for all 
interventions (predictor effect); and (b) is this ef-
fect different for CBTs relative to other interventions 
(moderation effect)?
MEthOd
study registration and management
This IPD-MA will be conducted in accordance with 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses guidelines,26 and is registered on PROS-
PERO. Regular email updates will be used to inform 
the collaborating network of our activities. Encrypted 
electronic data sharing clouds and email will be used to 
exchange data and paperwork between researchers.
Criteria for included studies
Types of studies
Included studies will be both controlled and uncontrolled 
clinical trials. Studies may be randomised at patient level, 
cluster-randomised or non-randomised. For crossover 
design studies, only data for the initial phase (ie, pre 
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crossover) will be used. Articles must be published in 
English. Unpublished data will be actively sought; hence, 
non-peer-reviewed studies will also be included. Sensi-
tivity analyses will be completed to evaluate the impact of 
study type on our results.
Participants
Studies must have recruited participants aged 18 years 
or older. Participants must have a diagnosis of major 
depressive disorder (MDD) according to the Diagnostic 
and Statistical Manual of Mental Disorders (any edition) 
or International Classification of Diseases (any edition) 
criteria, assessed via a structured clinical interview (eg, 
Structured Clinical Interview for DSM Disorders; Mini 
International Neuropsychiatric Interview). As depres-
sion-related deficits in autobiographical memory are 
evident into remission16 and National Institute of Health 
and Care Excellence guidelines recommend that CBT 
interventions are used to reduce depressive relapse (eg, 
MBCT),27 participants may either be experiencing a 
current major depressive episode, or remitted from MDD.
Autobiographical memory
Studies must include an objective measure of the speci-
ficity of autobiographical memory. This may be indexed 
using a cued-recalled task (eg, the autobiographical 
memory task),28 an interview29 or sentence completion 
procedure30 but responses must be scored for the number 
of specific, single incident memories retrieved.
Intervention
We will include studies evaluating any psychological 
therapy for depression which is cognitively based as per 
the Beck model (eg, cognitive therapy, CBT, mindful-
ness-based cognitive therapy). This will be determined 
by two independent reviewers using the author’s inter-
vention description. Interventions may be self-guided 
or therapist-guided, and delivered in-person or online, 
and in individual or group-based format. Excluded inter-
ventions will be those which directly aim to improve a 
defined cognitive process or bias (eg, cognitive/atten-
tion/interpretative bias modification, autobiographical 
memory-based intervention, concreteness training).
Comparison condition
Studies may include no comparison condition (ie, uncon-
trolled trials) or may include any type of comparison 
condition. Comparison conditions are anticipated to be 
waitlist, any psychosocial intervention (eg, psychoeduca-
tion, counselling) or antidepressant medication. Again, 
condition type will be determined by two independent 
reviewers based on the author’s intervention descrip-
tion. CBTs will be compared (1) against waitlist control 
(to index effects against natural recovery), (2) against all 
other interventions, (3) against other psychological inter-
ventions alone and (4) against antidepressant medication 
alone.
Coprimary outcomes
For question 1, the primary outcome will be autobi-
ographical memory specificity at postintervention. This 
will be operationalised as the proportion of specific, single 
incident memories reported by the participant during an 
objective measure of autobiographical memory. Speci-
ficity of memories will be rated by researchers (not partic-
ipants). Proportions (number specific/number of trials) 
will be calculated for any studies reporting the number of 
specific memories.
For question 2, the coprimary outcomes will be treat-
ment response at postintervention, indexed as (1) a score 
on a continuous measure of depressive symptoms and 
(2) diagnostic status, as rated using a standardised clini-
cian-administered interview. In situations where more 
than one continuous measure of depression is adminis-
tered, the Beck Depression Inventory II (BDI-II) will be 
preferred in analysis as this has been specifically devised 
to measure changes following CBT interventions. Any 
studies reporting Beck Depression Inventory I scores will 
be converted to BDI-II scores using the method outlined 
in the BDI-II manual.31
Secondary outcomes
As it is highly desirable for an intervention to produce 
stable, lasting change, follow-up assessments will be consid-
ered as secondary outcomes. The secondary outcomes 
for question 1 will be autobiographical memory speci-
ficity (as per defined above) at follow-up assessments. 
The secondary outcome for question 2 will be depressive 
symptoms and diagnostic status (as per defined above) at 
follow-up assessments.
Follow-up lengths to be included are assessments 
between 1 month and 2 years following the completion 
of therapy. During analysis, studies including a follow-up 
assessment between 1 and 3 months postintervention will 
be grouped to form a short-term follow-up, and any later 
assessment points will be grouped per 6-month period (ie, 
6 and 12 months). This will result in analysis of follow-up 
outcomes in the short-term (1–3 months), and at 6, 12, 18 
and 24 months postintervention.
Moderator
For question 2, the moderating variable will be the 
proportion of specific, single incident memories reported 
by the participant during an objective measure of autobi-
ographical memory at baseline.
search methods for identification of studies
Collaborative network
We have formed a collaborative network of experts in the 
role of autobiographical memory in depression. Through 
our own work and knowledge of the field, we have initially 
identified and obtained access to four individual datasets 
which provide the data necessary to analyse our research 
questions. Using this network to identify other potential 
datasets for inclusion, we will email the autobiographical 
memory and psychopathology special interest group, and 
 o
n
 19 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031110 on 12 June 2019. Downloaded from 
4 Hitchcock C, et al. BMJ Open 2019;9:e031110. doi:10.1136/bmjopen-2019-031110
Open access 
the collaborators of each member of our network. We 
will also make use of social media such as Twitter to raise 
awareness of the IPD-MA. This mode of identification is 
important, as we anticipate that many of the trials which 
have included an autobiographical memory measure 
may not list the measure in the Method section of the 
published paper. Indeed, this is the case for the majority 
of the datasets the collaborative network has already 
identified.
Electronic searches
As we anticipate that many of the trials which have 
included an autobiographical memory measure may not 
list this measure in the published paper, a multistage 
search strategy will be completed in order to identify all 
potential datasets (see figure 1). 
First, searches will be completed in PsycINFO, Medline, 
Web of Science, Cochrane database and WHO trials data-
base, using the string: cognitive therapy AND depres-
sion AND trial AND any flag words (with OR inserted 
between every flag word*) we have identified as markers 
of papers which may potentially include an autobiograph-
ical memory measure. These flag words were identified 
by evaluating common terminology in the abstracts 
of the four datasets identified through the collabora-
tion network. These terms are ‘mechanism,’ ‘process’, 
‘memory’, ‘cognitive function’, ‘negative thinking’, 
‘rumination’, ‘depressogenic thinking’ and ‘autobi-
ographical memory’. We use the term ‘cognitive therapy’ 
although we will also include CBTs as use of the term 
‘cognitive behavioural therapy’ may miss studies which 
administer cognitive therapy. Conversely, searches using 
the term cognitive therapy did identify evaluations of 
CBTs. Searches will be restricted to papers published in 
or after 1986 as this was the year that the seminal paper 
on autobiographical memory specificity in depression was 
published.28 The full electronic search strategy is avail-
able in the online supplementary materials.
Search results will be imported into Rayyan (a 
web-based tool for managing systematic reviews) by an 
administrator (Kuhn) and duplicates will be removed. 
This will allow for blind screening by two independent 
reviewers (Rudokaite and Patel). Papers deemed ineli-
gible from title and abstract by both reviewers will be set 
aside. Full text of the remaining papers will be examined 
independently by the reviewers to determine eligibility. 
Any discrepancy in inclusion will be resolved via discus-
sion with Hitchcock, or if necessary, by contacting the 
study authors for clarification.
Next, a secondary screening will be completed in order 
to identify studies which may have measured autobi-
ographical memory but not reported on it in the published 
paper. Through searches in Medline, PsycINFO and Web 
of Science using the terms autobiographical memory 
AND depression, we will produce a list of authors who 
have ever published on autobiographical memory and 
depression. This list will then be cross-referenced with the 
results of the primary database search. For studies with an 
author who has previously published on autobiographical 
memory, corresponding authors will then be emailed to 
enquire about unpublished autobiographical memory 
data.
The electronic search was conducted between 
December 2018 and February 2019.
data collection
Corresponding authors of eligible studies will be emailed 
to request data. A reminder email will be sent every 
2 weeks. If an author does not respond after 1 month, 
another author of the study will be contacted. A second 
attempt to contact this author will follow and so forth 
until a maximum of three authors are contacted. Study 
data will be considered unavailable if no study authors 
have responded to multiple contact attempts, or if authors 
indicate that they no longer have access to the data.
The authors will be able to supply data via email or an 
encrypted online data sharing service operated by the 
University of Cambridge. A single author will be identi-
fied for each study to whom all queries about the data 
collection processes and transformation of individual vari-
ables will be addressed. When researchers are cleaning a 
specific data set they may communicate with the original 
investigators via telephone discussions or by email.
data extraction, quality checks and storage
In accordance with Cochrane recommendations, both 
published and unpublished measures will be collected 
for all studies. IPD for specified variables (presented in 
table 1) will be extracted into a single dataset. For all 
outcomes, unimputed and untransformed data will be 
preferred. Spot checks will be completed to ensure data 
quality. The pattern of treatment allocation for each 
included study will be checked to ensure that blinding, 
randomisation and allocation sequence appear appro-
priate, in accordance with guidelines recommended by 
Tierney et al.32 Data will be stored in password-protected 
files on an encrypted University of Cambridge server, and 
will not include any personally identifiable information.
risk of bias
For individual studies, risk of bias will be evaluated 
using the Revised Cochrane Risk of Bias Tool33 to access 
study quality and risk of bias due to the randomisation 
process, deviations from intended interventions, missing 
outcome data, measurement of the outcome, selection 
of the reported result and other biases such as conflicts 
of interest. Using the tool, each study will be rated as of 
high, low or unclear risk. In order to reduce attrition bias, 
data will be checked against trial Consolidated Standards 
of Reporting Trials diagrams to ensure that data from all 
randomised participants are included.
strategy for data synthesis
Intent-to-treat analysis will be completed using data 
imputed at within-study level (if missing at random 
assumptions are met). Between-study heterogeneity 
will be indexed using the tau statistic. As there are now 
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multiple IPD-MAs establishing the effect of CBTs on 
depressive outcomes,34 35 we will proceed directly to eval-
uating moderation effects.
All analyses will be completed using random-effects 
models employing restricted maximum likelihood esti-
mation. However, if there is considerable heterogeneity 
in the quality of studies (indexed by the Cochrane Risk 
of Bias Tool) sensitivity analysis will be completed using 
fixed-effects models such that poorer quality studies will 
not receive equal weighting. If IPD are available for more 
than seven studies, prediction intervals will be used.36 If 
we obtain sufficient power, subsets of studies will be anal-
ysed to explore whether the below effects vary based on 
trauma history (as trauma exposure may reduce memory 
Figure 1 Identification of eligible datasets.  
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specificity),37 depressive severity and type of therapy (eg, 
MBCT, CBT).
Question 1
The effect of intervention on autobiographical memory 
specificity will be analysed using an Analysis of Cova-
riance (ANCOVA) random treatment effect one-stage 
model with random intercept and memory specificity 
baseline adjustment with different residual variance per 
study. Sensitivity analysis will be completed using strati-
fied intercepts.
Question 2
To determine whether autobiographical memory spec-
ificity moderates treatment response, a two-stage model 
predicting post-treatment depressive symptoms with base-
line symptom adjustment is planned to allow synthesis 
of datasets which used different symptom measures (eg, 
BDI-II and Hamilton Depression Rating Scale). The 
interaction term (baseline score x treatment type) will 
be estimated per trial, then pooled in a random-effects 
meta-analysis. Sensitivity analysis will next be completed 
using separate one-stage models for different depres-
sive symptom measures. Patient-level covariates will be 
centred to separate within-trial and across-trial effects.
Effects on diagnostic status will be analysed using 
a one-stage logistic model with random intercept to 
account for correlation between the interaction esti-
mate and other parameter estimates. Again, patient-level 
covariates will be centred to separate within-trial and 
across-trial effects. Sensitivity analysis will be completed 
using stratified intercepts. If the one-stage model fails to 
converge, a two-stage model will be completed.
Ethics and dissemination
Contributing studies will be asked to provide evidence 
of local ethical committee approval and to demonstrate 
that informed consent has been given to share deiden-
tifed data. Contributing studies will also be required to 
remove patient identifiers before providing their data. 
This includes date of birth, which will be converted to 
age at time of assessment. A data-sharing agreement will 
be signed between the authors of included studies and 
the IPD-MA research team. The resulting IPD-MA dataset 
will be shared through the MRC Cognition and Brain 
Sciences Unit Data Repository (accessed via www. mrc- 
cbu. cam. ac. uk/ publications/ opendata/) in accordance 
with open-science practices.
Patient and public involvement
Members of the patient and public involvement group 
formed by individuals with lived experience of depression 
discussed the project and the role of specificity in CBTs, 
and will contribute to dissemination of results.
Contributors CH, TD and EW designed the project. JR, SP, AS and IK contributed to 
study methods. All authors contributed to writing the paper.
Funding This work was funded by an ESRC grant (Ref: ES/R010781/1) awarded to 
the first author. 
Competing interests None declared.
Patient consent for publication Not required.
Table 1 Individual patient data to be extracted from included studies
Trial-level data Patient characteristics Outcomes
Trial identifier Anonymised participant identifier Post-treatment self-reported depressive 
symptoms
Country of completion Age Follow-up self-reported depressive 
symptoms
Type of CBT Gender Diagnostic status at post-treatment
Type of comparison group/s Education history Diagnostic status at follow-up
Format of treatment (individual, group) Ethnicity Post-treatment score for proportion of 
specific memories
Length of treatment in weeks Concurrent treatment use (eg, 
medication)
Post-treatment score for proportion of 
non-specific memories
Information about risk of bias
Trial design
Pre-treatment self-reported depressive 
symptoms
Follow-up score for proportion of specific 
memories
Pre-treatment score for number of 
specific memories
Follow-up score for proportion of non-
specific memories
Pre-treatment score for number of non-
specific memories
Any potential cognitive covariates 
(eg, rumination, working memory, IQ, 
executive function)
Reasons for missing data
CBT, cognitive behavioural therapy; IQ, Intelligence Quotient.
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Ethics approval Ethics approval was obtained from the Cambridge Psychology 
Research Ethics Committee (Identifier PRE.2017.100). 
Provenance and peer review Not commissioned; peer reviewed for ethical and 
funding approval prior to submission.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
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